30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

24 July 2026 As Philips' Kevin Scott becomes the IP Federation’s new president, Sarah Speight discovers the key issues facing the membership body for in-house counsel.

MedTech

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

23 July 2026 The latest clash between two facial aesthetics rivals centres on a Swiss rival’s newly approved syringe, which AbbVie and Allergan claim infringes five US design patents.

Regulation & Industry

Trump slaps 100% tariff on generic drugs in US manufacturing push

23 July 2026 Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.